A pharmacoepidemiological nested case-control study of risk factors for venous thromboembolism with the focus on diabetes, cancer, socioeconomic group, medications, and comorbidities
Diabetes and Vascular Disease Research · 2024
DOI: 10.1177/14791641241236894 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Diabetes and Vascular Disease Research, 2024. Verfasst von Lasse Myllylahti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Neoplasms, Comorbidity, Venous Thromboembolism, Pharmacoepidemiology. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helsinki University Library.
Themen: Thromboseprophylaxe, Diabetes mellitus
Abstract (Originalsprache)
Objectives
A pharmacoepidemiological study to assess VTE risk factors in a diabetes-rich population.
Methods
The study comprised 299,590 individuals. We observed 3450 VTEs and matched them with 15,875 controls using a nested case-control approach and collected data on comorbidities and prescriptions. By multivariable conditional logistic regression, we calculated ORs with 95%CIs for comorbidities and medications to evaluate their associations with VTE.
Results
Diabetes (aOR 2.16; 95%CI 1.99–2.34), inflammatory bowel disease (1.84; 1.27–2.66), and severe psychiatric disorders (1.72; 1.43–2.05) had the strongest associations among the non-cancer comorbidities. Pancreatic (12.32; 7.11–21.36), stomach (8.57; 4.07–18.03), lung and bronchus (6.26; 4.16–9.43), and ovarian (6.72; 2.95–15.10) cancers were ranked as high-risk for VTE. Corticosteroids, gabapentinoids, psychotropic drugs, risedronic acid, and pramipexole were most strongly associated (aOR exceeding 1.5) with VTE. Insulin (3.86; 3.33–4.47) and sulphonylureas (2.62; 2.18–3.16) had stronger associations than metformin (1.65; 1.49–1.83). Statins and lercanidipine (0.78; 0.62–0.98) were associated with a lowered risk of VTE.
Conclusions
In this cohort, with 50% diabetes prevalence, pancreatic, stomach, lung and bronchus, and ovarian cancers were strongly associated with VTE. Corticosteroids, gabapentinoids, and psychotropic medications had the strongest associations with VTE among medications. This may be valuable for generating hypotheses for the further research. Lercanidipine may be a novel protective medication against VTE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
- Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland.
- Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
- Unit of Coagulation Disorders, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
- Research Program Unit in Systems Oncology, University of Helsinki, Helsinki, Finland.
- The Finnish Institute of Health and Welfare, Helsinki, Finland.
ORCID-Profile: Lasse Myllylahti
Förderung
- Helsinki University Library
Zitieren
APA
Myllylahti, L., Niskanen, L., Lassila, R., & Haukka, J. (2024). A pharmacoepidemiological nested case-control study of risk factors for venous thromboembolism with the focus on diabetes, cancer, socioeconomic group, medications, and comorbidities. Diabetes and Vascular Disease Research. https://doi.org/10.1177/14791641241236894
Vancouver
Myllylahti L, Niskanen L, Lassila R, Haukka J. A pharmacoepidemiological nested case-control study of risk factors for venous thromboembolism with the focus on diabetes, cancer, socioeconomic group, medications, and comorbidities. Diabetes and Vascular Disease Research. 2024. doi:10.1177/14791641241236894
BibTeX
@article{Myllylahti2024,
author = {Myllylahti, Lasse and Niskanen, Leo and Lassila, Riitta and Haukka, Jari},
title = {A pharmacoepidemiological nested case-control study of risk factors for venous thromboembolism with the focus on diabetes, cancer, socioeconomic group, medications, and comorbidities},
journal = {Diabetes and Vascular Disease Research},
year = {2024},
doi = {10.1177/14791641241236894}
}
EUVIMED